Repatha (evolocumab) is a monoclonal antibody lipid-lowering therapy used to reduce LDL-C and cardiovascular risk in patients with established cardiovascular disease and familial hypercholesterolemia populations. The label describes it as targeting PCSK9 to increase LDL receptor availability and LDL clearance. U.S. approval was first granted in 2015.
Barclays initiated Amgen with an Equal Weight rating and a $185 price target as debate over the Phase 3 MARITIME trial continued. Amgen said 2025 revenue and earnings per share rose by double digits.
Pharmaceutical companies are delaying European drug launches due to uncertainty over U.S. pricing policies under President Trump. New drug launches in EU markets fell 35% following Trump's executive order on international reference pricing. Companies fear lower European prices could undermine their ability to maintain higher prices in the $700 billion U.S. market.
Amgen shares have climbed 35% over six months, trading near $388, as analysts raise price targets following strong fourth-quarter 2025 results and expanding oncology pipeline programs including IMDELLTRA and LUMAKRAS.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT04573777 |
Reducing Intracranial atheroSclErosis With Repatha |
TERMINATED | PHASE4 |
